HWAM
ACAD icon

Hennion & Walsh Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
103,290
+2,561
+3% +$56.3K 0.07% 319
2026
Q1 		$2.24M Sell
100,729
-3,117
-3% -$74.5K 0.08% 319
2025
Q4 		$2.77M Sell
103,846
-27,885
-21% -$666K 0.1% 275
2025
Q3 		$2.81M Sell
131,731
-8,390
-6% -$198K 0.1% 260
2025
Q2 		$3.02M Buy
140,121
+9,060
+7% +$168K 0.12% 218
2025
Q1 		$2.18M Buy
131,061
+27,736
+27% +$504K 0.1% 254
2024
Q4 		$1.9M Buy
103,325
+7,491
+8% +$121K 0.09% 301
2024
Q3 		$1.47M Sell
95,834
-6,643
-6% -$111K 0.07% 361
2024
Q2 		$1.67M Sell
102,477
-40,521
-28% -$654K 0.09% 293
2024
Q1 		$2.64M Buy
142,998
+27,871
+24% +$691K 0.14% 201
2023
Q4 		$3.6M Sell
115,127
-24,912
-18% -$595K 0.21% 127
2023
Q3 		$2.92M Sell
140,039
-11,068
-7% -$301K 0.19% 134
2023
Q2 		$3.62M Sell
151,107
-60,670
-29% -$1.35M 0.21% 116
2023
Q1 		$3.99M Buy
211,777
+3,028
+1% +$57.7K 0.24% 102
2022
Q4 		$3.32M Buy
208,749
+8,717
+4% +$136K 0.21% 129
2022
Q3 		$3.27M Buy
200,032
+2,117
+1% +$34.3K 0.22% 123
2022
Q2 		$2.79M Sell
197,915
-13,577
-6% -$253K 0.17% 154
2022
Q1 		$5.12M Buy
211,492
+21,337
+11% +$516K 0.27% 95
2021
Q4 		$4.44M Buy
190,155
+8,692
+5% +$175K 0.22% 126
2021
Q3 		$3.01M Buy
181,463
+13,364
+8% +$258K 0.16% 188
2021
Q2 		$4.1M Buy
168,099
+8,975
+6% +$203K 0.22% 118
2021
Q1 		$4.11M Buy
+159,124
New +$7M 0.25% 105

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hennion & Walsh Asset Management's ACAD Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 2.5% in Q2 2026, buying an estimated $56.3K and bringing the position to 103,290 shares worth $2.61M. The position accounts for 0.07% of the portfolio, ranked #319.

Hennion & Walsh Asset Management first reported a position in ACAD in Q1 2021 and has held it in 22 quarters since. The position peaked at $5.12M in Q1 2022. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Hennion & Walsh Asset Management held 103,290 shares of Acadia Pharmaceuticals worth $2.61M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 2,561 Acadia Pharmaceuticals shares in Q2 2026, an estimated $56.3K.
  • Acadia Pharmaceuticals made up 0.07% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #319 holding.
  • Hennion & Walsh Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Hennion & Walsh Asset Management's Acadia Pharmaceuticals position peaked at $5.12M in Q1 2022.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.